Study of adebrelimab plus chemo and simvastatin for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy (gemcitabine and cisplatin), and a cholesterol-lowering drug (simvastatin) for advanced bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if the addition of simvastatin improves treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced bile duct or gallbladder cancer that has spread and cannot be surgically removed.
- You must not have received prior chemotherapy or other systemic therapy for advanced disease, unless it has been more than 6 months since surgery or adjuvant treatment.
- Your daily performance level must be at least 0 or 1 on the ECOG scale (able to carry out normal activity without help or limited activity but able to do light work).
- You must have at least one measurable tumor on a CT scan (at least 1 cm in size or a lymph node at least 1.5 cm).
- Your major organs (heart, lungs, brain, etc.) must be working well without severe problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
This trial tests a combination of three drugs—envafolimab (an immunotherapy), chemotherapy, and simvastatin (a cholesterol medicine)—for people with advanced bile duct or gallbladder cancer that hasn't been treated yet or came back after surgery. The goal is to see if adding simvastatin helps the treatment work better.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
Hear when a new Advanced Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.